BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2141516)

  • 1. CSF drug levels for children with acute lymphoblastic leukemia treated by 5 g/m2 methotrexate. A study from the EORTC Children's Leukemia Cooperative Group.
    Milano G; Thyss A; Serre Debeauvais F; Laureys G; Benoit Y; Deville A; Dutour C; Robert A; Otten J; Behar C
    Eur J Cancer; 1990 Apr; 26(4):492-5. PubMed ID: 2141516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
    Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
    Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid drug levels of leukemic children receiving intravenous 5 g/m2 methotrexate.
    Millot F; Rubie H; Mazingue F; Mechinaud F; Thyss A
    Leuk Lymphoma; 1994 Jun; 14(1-2):141-4. PubMed ID: 7920221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cerebrospinal fluid methotrexate level in children treated with medium-high and high doses of the drug].
    Wysocki M; Balcar-Boroń A; Krzyzanowski M; Szadujkis-Szadurski L; Ozyński T; Nowaczyk-Michalak A
    Acta Haematol Pol; 1992; 23(3):185-90. PubMed ID: 1492543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic drug monitoring of methotrexate in cerebrospinal fluid after systemic high-dose infusion in children: can the burden of intrathecal methotrexate be reduced?
    Niemann A; Mühlisch J; Frühwald MC; Gerss J; Hempel G; Boos J
    Ther Drug Monit; 2010 Aug; 32(4):467-75. PubMed ID: 20571463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 7-Hydroxymethotrexate concentrations in serum and cerebrospinal fluid of children with acute lymphoblastic leukemia.
    Borsi JD; Sagen E; Romslo I; Slørdal L; Moe PJ
    Cancer Chemother Pharmacol; 1990; 27(2):164-7. PubMed ID: 2249335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variability in methotrexate serum and cerebrospinal fluid pharmacokinetics in children with acute lymphocytic leukemia: relation to assay methodology and physiological variables.
    Seidel H; Andersen A; Kvaløy JT; Nygaard R; Moe PJ; Jacobsen G; Lindqvist B; Slørdal L
    Leuk Res; 2000 Mar; 24(3):193-9. PubMed ID: 10739001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of dose and repeat intravenous 24 hr infusions of methotrexate on cerebrospinal fluid availability in children with hematological malignancies.
    Thyss A; Milano G; Deville A; Manassero J; Renee N; Schneider M
    Eur J Cancer Clin Oncol; 1987 Jun; 23(6):843-7. PubMed ID: 3477462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion.
    Evans WE; Hutson PR; Stewart CF; Cairnes DA; Bowman WP; Rivera G; Crom WR
    Clin Pharmacol Ther; 1983 Mar; 33(3):301-7. PubMed ID: 6600662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Investigation on individualized adjustment of target range of high-dose methotrexate].
    Hua Y; Zhao WH; Lu XT; Yang LH; Lu W
    Zhonghua Er Ke Za Zhi; 2008 Mar; 46(3):203-8. PubMed ID: 19099710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
    Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
    J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study on the pharmacokinetics of 7-hydroxy-methotrexate after administration of methotrexate in the dose range of 0.5-33.6 g/m2 to children with acute lymphoblastic leukemia.
    Borsi JD; Sagen E; Romslo I; Moe PJ
    Med Pediatr Oncol; 1990; 18(3):217-24. PubMed ID: 2329967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL).
    Skärby T; Jönsson P; Hjorth L; Behrentz M; Björk O; Forestier E; Jarfelt M; Lönnerholm G; Höglund P
    Cancer Chemother Pharmacol; 2003 Apr; 51(4):311-20. PubMed ID: 12721759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose methotrexate as part of remission maintenance therapy for childhood acute lymphocytic leukemia: a Pediatric Oncology Group pilot study.
    Frankel LS; Wang YM; Shuster J; Nitschke R; Doering EJ; Pullen J
    J Clin Oncol; 1983 Dec; 1(12):804-9. PubMed ID: 6583318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma homocysteine in children with acute lymphoblastic leukemia: changes during a chemotherapeutic regimen including methotrexate.
    Refsum H; Wesenberg F; Ueland PM
    Cancer Res; 1991 Feb; 51(3):828-35. PubMed ID: 1988122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
    Joannon P; Oviedo I; Campbell M; Tordecilla J
    Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study.
    Camitta B; Mahoney D; Leventhal B; Lauer SJ; Shuster JJ; Adair S; Civin C; Munoz L; Steuber P; Strother D
    J Clin Oncol; 1994 Jul; 12(7):1383-9. PubMed ID: 8021728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid and plasma methotrexate levels following high-dose regimen given as a 3-hour intravenous infusion in children with nonHodgkin's lymphoma.
    Vassal G; Valteau D; Bonnay M; Patte C; Aubier F; Lemerle J
    Pediatr Hematol Oncol; 1990; 7(1):71-7. PubMed ID: 2397170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia.
    Donelli MG; Zucchetti M; Robatto A; Perlangeli V; D'Incalci M; Masera G; Rossi MR
    Med Pediatr Oncol; 1995 Mar; 24(3):154-9. PubMed ID: 7838036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of cerebrospinal fluid beta-glucuronidase activity with plasma methotrexate concentrations in leukemic children receiving high-dose methotrexate.
    Vlacha V; Eliopoulou M; Haidas S; Beratis NG
    Pediatr Blood Cancer; 2004 Apr; 42(4):350-6. PubMed ID: 14966832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.